Online inquiry

IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5963MR)

This product GTTS-WQ5963MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5963MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5934MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ2758MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ8105MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ2297MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ8779MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ15330MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ3209MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW